HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Официальное название

Hepatic Arterial Infusion or Intravenous Infusion of Adebrelimab, Combined With Bevacizumab and Hepatic Arterial Infusion of FOLFOX Chemotherapy for Advanced Hepatocellular Carcinoma: a Multicenter, Open Label, Randomized Phase II Trial

Обзор

The purpose of this study is to evaluate the efficacy and safety of Adabrelimab (arterial or intravenous administration) combined with hepatic artery FOLFOX infusion chemotherapy and Bevacizumab as the first-line treatment of advanced stage hepatocellular carcinoma. Patients will be randomized 1:1 etither to receive hepatic arterial infusion(HAI) Adabrelimab group or IV Adabrelimab group, and both groups will receive HAI FOLFOX chemotherapy and IV Bevacizumab.

Подробное описание

The combination of anti-PD-L1 antibody and bevacizumab has been approved as the first-line treatment for advanced hepatocellular carcinoma (HCC). However, the overall response rate is still unsatisfactory and the prognosis of patients remains poor. Our previous retrospective analysis showed triple combination of hepatic arterial infusion chemotherapy (HAIC) of FOLFOX regimen plus adebrelimab (anti-PD-L1 antibody) and bevacizumab had a high response rate for advanced stage HCC patients. More, as the PD-L1 on intrahepatic tumors is the main target of anti-PD-L1 therapy, hepatic arterial infusion of anti-PD-L1 antibody may contribute to a synergistic effect. Herein, we aimed to evaluate the efficacy and safety of Adabrelimab (arterial or intravenous administration) combined with hepatic artery FOLFOX infusion chemotherapy and Bevacizumab as the first-line treatment of advanced stage hepatocellular carcinoma.

Вмешательства

• Процедура HAI Adebrelimab
  Hepatic arterial infusion (HAI) of Adebrelimab (ADE) (1200mg, IA, Q3W)
• Препарат intravenous infusion (IV) of Adebrelimab (ADE)
  intravenous infusion (IV) of Adebrelimab (ADE) (1200mg, IV, Q3W)
• Препарат intravenous infusion (IV) of Bevacizumab (Bev.)
  intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W)
• Процедура HAIC with FOLFOX regimen
  HAIC with FOLFOX regimen (oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil bolus 400 mg/m2 on day 1, and 5-fluorouracil infusion 2500 mg/m2 for 46 hours via hepatic artery Q4W)
• Препарат Adebrelimab and bevacizumab maintainance treatment
  The two arms continue the triple combination treatment up to 6 cycles and then received receive intravenous combination therapy of adebrelimab and bevacizumab for maintainance until disease progression or intolerable toxicity

Первичные конечные точки

• Objective response rate (ORR) [Срок оценки: 6 weeks]

Вторичные конечные точки (7)

• Progression-free survival (PFS) [Срок оценки: 36 months]
• Overall survival(OS) [Срок оценки: 36 months]
• Time to progression [Срок оценки: 36 months]
• Disease control rate [Срок оценки: 36 months]
• Duration of response [Срок оценки: 36 months]
• Best overall response [Срок оценки: 36 months]
• Incidence and Severity of Adverse Events (AEs) [Срок оценки: From the date of informed consent signature up to 30 days after the last dose of study treatment]

Критерии участия

Критерии включения

• Voluntarily participate in the study and sign the informed consent form;
• Aged ≥18 years (calculated as of the date of signing the informed consent form);
• Diagnosed with hepatocellular carcinoma (HCC) by clinical or pathological means;
• Barcelona Clinic Liver Cancer (BCLC) stage C, with vascular/bile duct invasion or distant metastasis (excluding cases with Vp4-type tumor thrombus);
• No prior systemic therapy for HCC; or progression or residual lesions following prior local therapy for HCC (including but not limited to surgery, ablation, radiotherapy, or transarterial chemoembolization \[TACE\]), with an interval of at least one month between the last local treatment and enrollment;
• ECOG Performance Status (PS) score of 0-1 and Child-Pugh grade A or grade B with a score of 7;
• No history of autoimmune disease;
• An expected survival time of ≥3 months;
• At least one measurable lesion (per RECIST v1.1 criteria, the longest diameter of the measurable lesion on spiral CT scan must be ≥10 mm or the short axis of enlarged lymph nodes must be ≥15 mm; lesions previously treated locally can be considered target lesions if progression is confirmed per RECIST v1.1 criteria);
• Sufficient hematologic, hepatic, and renal function, with laboratory tests within the following parameters performed within one week prior to enrollment:

• Neutrophil count ≥1.5×10\^9/L;

• Platelet count ≥75×10\^9/L;

• Hemoglobin ≥90 g/L;

• Serum ALT and AST ≤5×upper limit of normal (ULN); ⑤ Serum creatinine ≤1.5×ULN; ⑥ International Normalized Ratio (INR) <2.3, or prothrombin time ≤ULN+6 seconds; ⑦ Albumin ≥30 g/L;

• Total bilirubin ≤3×ULN.
• Women of childbearing potential must have a negative serum or urine pregnancy test within seven days prior to study enrollment, must not be breastfeeding, and must agree to use contraceptive measures during the study and for six months after its conclusion; men must agree to use contraceptive measures during the study and for six months after its conclusion.

Критерии исключения

• Patients with a severe allergy to iodine contrast agents who are unable to undergo hepatic arterial infusion chemotherapy (HAIC);
• Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes within one month prior to randomization;
• Active infections that cannot be effectively controlled;
• Severe gastroesophageal varices; untreated or incompletely treated gastroesophageal varices (with bleeding or high risk of bleeding);
• Presence of brain metastases or bone metastases requiring urgent surgical or radiotherapy intervention;
• Pregnant or suspected to be pregnant, or currently breastfeeding;
• Current use or recent use (within 10 days before the initiation of the study treatment) of aspirin (>325 mg/day, maximum antiplatelet dose) or dipyridamole, ticlopidine, clopidogrel, and cilostazol;
• Thrombotic or embolic events, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, or cerebral infarction) or pulmonary embolism, occurring within six months prior to the initiation of the study treatment;
• Congenital or acquired immunodeficiency;
• History of other malignant tumors;
• Any of the following conditions within 12 months prior to the initiation of the study: myocardial infarction, severe/unstable angina, or congestive heart failure;
• Renal insufficiency requiring dialysis;
• History of organ transplantation;
• Severe acute or chronic physical or mental illnesses or laboratory abnormalities that may increase study risks or interfere with result interpretation, rendering the patient unsuitable for enrollment.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 3 центра

• Gansu Province Cancer Hospital — Lanzhou
• Sun Yat-sen University Cancer Center — Гуанчжоу
• Henan Cancer Hospital — Чжэнчжоу

Идентификаторы

NCT: NCT06737913 · B2024-588-01 · ChiCTR2400092928

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)
• ChiCTR ChiCTR2400092928 (Китайский реестр КИ)

Открыть это исследование на ClinicalTrials.gov ↗